572
Views
22
CrossRef citations to date
0
Altmetric
Endometrium and Disease

The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer: a pilot study

, &
Pages 559-561 | Received 19 Jul 2011, Accepted 09 Nov 2011, Published online: 02 Feb 2012

References

  • Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581–592.
  • Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents. Vol. VIII. Lyon: IARC Press; 2002. pp 310–486.
  • Bray F, Dos Santos Silva I, Moller H, Weiderpass E. Endometrial cancer incidence trends in Europe: underlying determinants and. prospects for prevention. Cancer Epidemiol Biomarkers Prev 2005;14:1132–1142.
  • Pashov AI, Diduk OV. The nature of a cancer of a body of a uterus in Krasnoyarsk edge. Obstetrics and Gynecology Pressing Questions: The Collection of Proceedings. Krasnoyarsk, 2009; 93–98.
  • Surrey ES, Hornstein MD. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstet Gynecol 2002;99:709–719.
  • Chernukha GE, Shigoreva TV, Mogirevskay OA. The effect of levonorgestrel releasing intrauterine system on endometrial hyperplasia. Gynecol Endocrinol 2006;22:255.
  • Kaunitz AM, Meredith S, Inki P, Kubba A, Sanchez-Ramos L. Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. Obstet Gynecol 2009;113:1104–1116.
  • Petta CA, Ferriani RA, Abrao MS, Hassan D, Rosa E Silva JC, Podgaec S, Bahamondes L. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod 2005;20:1993–1998.
  • Orbo A, Arnes M, Pettersen I, Larsen K, Hanssen K, Moe B. Down-regulated progesterone receptor A and B coinciding with successful treatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterine system. Acta Obstet Gynecol Scand 2010;89:1438–1446.
  • Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2010;203:547.e1–547.10.
  • Schriock ED. GnRH agonists. Clin Obstet Gynecol 1989;32:550–563.
  • Holland C. Unresolved issues in the management of endometrial cancer. Expert Rev Anticancer Ther 2011;11:57–69.
  • Bokhman JV, Chepick OF, Volkova AT, Vishnevsky AS. Can primary endometrial carcinoma stage I be cured without surgery and radiation therapy? Gynecol Oncol 1985;20:139–155.
  • Jeyarajah AR, Gallagher CJ, Blake PR, Oram DH, Dowsett M, Fisher C, Oliver RT. Long-term follow-up of gonadotrophin-releasing hormone analog treatment for recurrent endometrial cancer. Gynecol Oncol 1996;63:47–52.
  • Covens A, Thomas G, Shaw P, Ackerman I, Osborne R, Lukka H, Carey M, et al. A phase II study of leuprolide in advanced/recurrent endometrial cancer. Gynecol Oncol 1997;64:126–129.
  • Asbury RF, Brunetto VL, Lee RB, Reid G, Rocereto TF; Gynecologic Oncology Group. Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Am J Clin Oncol 2002;25:557–560.
  • Kohzo A, Misa D, Yumiko I, Seiichiro O. Differences between gonadotropin-releasing hormone agonist and oral contraceptives for the treatment of endometriosis. Obstet Gynecol 2005;105:63S.
  • Ayse S, Baris A, Bilhan S, Bulent U. Medical treatment of uterocutaneous fistula with gonadotropin-releasing hormone agonist administration. Obstet Gynecol 2008;111(2 Pt 2);526–528.
  • Mamoru M, Takashi Y, Hideto Y, Hisanori M. Effect of Gonadotropin-Releasing Hormone Agonist on a Uterine Arteriovenous Malformation. Obstet Gynecol 2006;108(3 Pt 2):751–753.
  • Farthing A. Conserving fertility in the management of gynaecological cancers. BJOG 2006;113:129–134.
  • Cade TJ, Quinn MA, Rome RM, Neesham D. Progestogen treatment options for early endometrial cancer. BJOG 2010;117:879–884.
  • Hahn HS, Yoon SG, Hong JS, Hong SR, Park SJ, Lim JY, Kwon YS, et al. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol Cancer 2009;19:1068–1073.
  • Signorelli M, Caspani G, Bonazzi C, Chiappa V, Perego P, Mangioni C. Fertility-sparing treatment in young women with endometrial cancer or atypical complex hyperplasia: a prospective single-institution experience of 21 cases. BJOG 2009;116:114–118.
  • Corrado G, Baiocco E, Carosi M, Vizza E. Progression of conservatively treated endometrial complex atypical hyperplasia in a young woman: a case report. Fertil Steril 2008;90:2006.e5–2006.e8.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.